Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OmniComm Systems, a leading global provider of clinical data management solutions for clinical trials, has announced that one of the world's largest contract research organizations (CRO) with annual revenues exceeding $2 billion, selected TrialMaster electronic data capture technology (EDC) to meet its current and future data management requirements for their expanding number of Phase I and Phase IIa clinical studies.
Subscribe to our email newsletter
These studies are the important first step in determining the safety and tolerability of new drugs. They test how drugs are absorbed into the body, and the amount of time a drug stays in the body.
The drug’s safety and side effects are also evaluated at varying dose levels during these studies.
TrialMaster’s intuitive user interface made it the ideal choice for this CRO’s Phase I and Phase IIa studies.
Additionally, TrialMaster’s single interface for data capture, data management and reporting was a significant factor in their selection of TrialMaster.
TrialMaster’s web-based technology provides investigators and this CRO complete access to clinical data. TrialMaster’s ability to integrate with other clinical technologies such as safety systems is another significant feature that drove the selection. TrialMaster also includes embedded eLearning, allowing their researchers to easily learn the system and quickly and accurately initiate trials.
"This is another clear signal from the market that OmniComm is viewed as the EDC specialist company," said Dr. Kuno van der Post, senior vice president of business development, OmniComm Systems.
"It is not just performance, reliability and scalability that make TrialMaster EDC ideal for Phase I and II trials but also its feature rich functionality that enables rapid trial set up, ensures data accuracy, and improves clinical trial productivity."